Table 4.
Univariate Survival Analysis
| Kaplan-Meier Analysis | Univariate Cox Regression | |||||
|---|---|---|---|---|---|---|
| Variable | N | Median OS months | 95% CI | H.R. | 95% CI | Wald test P value |
| All Patients | 376 | 30.8 | 24.7 – 36.9 | |||
| Gender | <0.001 | |||||
| Female | 227 | 39.1 | 27.2 – 51.0 | 1.00 | ||
| Male | 149 | 23.0 | 17.8 – 28.2 | 1.68 | 1.26 – 2.25 | |
| Race | 0.65 | |||||
| Caucasian | 295 | 33.0 | 25.9 – 40.0 | 1.00 | ||
| African American | 51 | 23.7 | 18.3 – 29.0 | 1.27 | 0.85 – 1.89 | |
| Asian American | 13 | 33.2 | 18.6 – 47.8 | 1.07 | 0.47 – 2.42 | |
| Other | 12 | 17.9 | ND | 1.33 | 0.55 – 3.26 | |
| Smoking status | 0.01 | |||||
| Never smoker | 78 | 53.0 | 24.4 – 81.6 | 1.00 | ||
| Ever smoker | 296 | 28.8 | 23.2 – 34.4 | 1.66 | 1.11 – 2.46 | |
| ECOG PS | <0.001 | |||||
| 0 | 125 | 43.0 | 30.0 – 55.9 | 1.00 | ||
| 1 | 149 | 24.4 | 16.1 – 32.8 | 1.33 | 0.94 – 1.90 | |
| 2+ | 34 | 14.9 | 13.2 – 16.6 | 2.57 | 1.64 – 4.04 | |
| Histology | 0.20 | |||||
| AdenoCA | 298 | 34.1 | 26.8 – 41.4 | 1.00 | ||
| Squamous | 30 | 22.1 | 9.0 – 35.2 | 1.64 | 1.03 – 2.60 | |
| Adenosquamous | 14 | 17.9 | 14.6 – 21.2 | 1.51 | 0.77 – 2.97 | |
| NOS* | 20 | 49.0 | 0.0 – 104.1 | 0.93 | 0.49 – 1.77 | |
| Large cell | 8 | 26.2 | 9.8 – 42.6 | 1.44 | 0.53 – 3.89 | |
| Original Stage | 0.10 | |||||
| I | 43 | 39.7 | 18.8 – 60.6 | 1.00 | ||
| II | 33 | 49.7 | 25.2 – 74.3 | 0.88 | 0.41 – 1.87 | |
| III | 121 | 27.1 | 22.2 – 31.9 | 1.36 | 0.76 – 2.44 | |
| IV | 179 | 28.8 | 19.7 – 38.0 | 1.60 | 0.91 – 2.80 | |
| EGFR Mutation (any) | 0.09 | |||||
| Positive | 60 | 46.8 | 26.4 – 67.3 | 1.00 | ||
| Negative | 303 | 29.6 | 22.9 – 36.3 | 1.48 | 0.95 – 2.32 | |
| EGFR Exon 19 Mutation | 0.09 | |||||
| Positive | 38 | 46.8 | 26.1 – 67.6 | 1.00 | ||
| Negative | 329 | 29.6 | 23.2 – 36.1 | 1.59 | 0.93 – 2.69 | |
| EGFR L858R Mutation | 0.70 | |||||
| Positive | 22 | ND | — | 1.00 | ||
| Negative | 343 | 30.8 | 24.5 – 37.0 | 1.16 | 0.54 – 2.48 | |
| KRAS Mutation status | 0.69 | |||||
| Mutant | 83 | 32.7 | 20.3 – 45.1 | 0.93 | 0.64 – 1.34 | |
| Wild type | 207 | 33.0 | 25.0 – 41.0 | 1.00 | ||
| Brain Metastases | 0.52 | |||||
| No | 290 | 32.7 | 25.0 – 40.4 | 1.00 | ||
| Yes | 85 | 28.8 | 19.7 – 37.9 | 1.11 | 0.80 – 1.54 | |
| Liver Metastases | 0.004 | |||||
| No | 333 | 35.4 | 28.6 – 42.2 | 1.00 | ||
| Yes | 42 | 20.3 | 15.3 – 25.4 | 1.79 | 1.20 – 2.67 | |
| Subcutaneous Metastases | 0.79 | |||||
| No | 370 | 30.8 | 24.5 – 37.0 | 1.00 | ||
| Yes | 5 | 16.8 | 0.0 – 64.9 | 1.15 | 0.42 – 3.11 | |
| Bone Metastases | 0.001 | |||||
| No | 265 | 39.1 | 26.7 – 51.5 | 1.00 | ||
| Yes | 110 | 24.4 | 17.2 – 31.7 | 1.62 | 1.20 – 2.18 | |
| Age | 1.02 | 1.00 – 1.03 | 0.01 | |||
| Charlson Comorbidity Index | 1.25 | 1.14 – 1.36 | <0.001 | |||
| Age-weighted Comorbidity Index | 1.20 | 1.12 – 1.29 | <0.001 | |||
HR = Hazard Ratio, CI = Confidence Interval
ND = Not defined
*
Not Otherwise Specified (Poorly Differentiated)